The effectiveness of immunotherapy as a cancer treatment has drawn more attention from the public recently. Since its durability is longer lasting than chemotherapy and it is effective for about 80% of lung cancer patients, immunotherapy is now viewed as the new preferred treatment for lung cancer. Together with the PDL-1 protein test to predict the response of individual patients to immunotherapy, the appropriate treatment can then be administered sooner. Patients no longer need to waste money and time receiving unsuitable treatment.
